title: AKT activation promotes PTEN hamartoma tumor syndrome-associated cataract development.
abstract: Mutations in the human phosphatase and tensin homolog (PTEN) gene cause PTEN hamartoma tumor syndrome (PHTS), which includes cataract development among its diverse clinical pathologies. Currently, it is not known whether cataract formation in PHTS patients is secondary to other systemic problems, or the result of the loss of a critical function of PTEN within the lens. We generated a mouse line with a lens-specific deletion of Pten (PTEN KO) and identified a regulatory function for PTEN in lens ion transport. Specific loss of PTEN in the lens resulted in cataract. PTEN KO lenses exhibited a progressive age-related increase in intracellular hydrostatic pressure, along with, increased intracellular sodium concentrations, and reduced Na+/K+-ATPase activity. Collectively, these defects lead to lens swelling, opacities and ultimately organ rupture. Activation of AKT was highly elevated in PTEN KO lenses compared to WT mice. Additionally, pharmacological inhibition of AKT restored normal Na+/K+-ATPase activity in primary cultured lens cells and reduced lens pressure in intact lenses from PTEN KO animals. These findings identify a direct role for PTEN in the regulation of lens ion transport through an AKT-dependent modulation of Na+/K+-ATPase activity, and provide a new animal model to investigate cataract development in PHTS patients.
authors.forename: Caterina
authors.initials: C
authors.lastname: Sellitto
authors.forename: Leping
authors.initials: L
authors.lastname: Li
authors.forename: Junyuan
authors.initials: J
authors.lastname: Gao
authors.forename: Michael L
authors.initials: ML
authors.lastname: Robinson
authors.forename: Richard Z
authors.initials: RZ
authors.lastname: Lin
authors.forename: Richard T
authors.initials: RT
authors.lastname: Mathias
authors.forename: Thomas W
authors.initials: TW
authors.lastname: White
mesh_terms: D000375:Aging; D000818:Animals; D002386:Cataract / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D018450:Disease Progression; D004789:Enzyme Activation; D005136:Eye Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D006223:Hamartoma Syndrome, Multiple / Q000150:complications*; D006874:Hydrostatic Pressure; D017136:Ion Transport / Q000502:physiology*; D007908:Lens, Crystalline / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D009928:Organ Specificity; D051059:PTEN Phosphohydrolase / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000502:physiology*; D012422:Rupture, Spontaneous; D012964:Sodium / Q000378:metabolism*; D000254:Sodium-Potassium-Exchanging ATPase / Q000502:physiology*
chemical_list: D005136:Eye Proteins; D012964:Sodium; C514862:Akt1 protein, mouse; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse; D000254:Sodium-Potassium-Exchanging ATPase